Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.26039
Abstract: This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an… read more here.
Keywords: newly diagnosed; term follow; myeloid leukemia; venetoclax plus ... See more keywords
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03902-9
Abstract: Dear editor, Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a distinctive and extremely aggressive subtype of T-ALL. It is characterized by the aberrant expression of myeloid/stem cell antigens and the lack of Tlymphoid antigens… read more here.
Keywords: relapsed refractory; plus hag; hag regimen; venetoclax plus ... See more keywords
Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyab112
Abstract: Abstract Background In a multinational phase 3 trial (VIALE-C), venetoclax plus low-dose cytarabine prolonged overall survival vs placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy, although it… read more here.
Keywords: low dose; dose cytarabine; venetoclax plus; plus low ... See more keywords
Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
Sign Up to like & getrecommendations! Published in 2022 at "Oncotarget"
DOI: 10.18632/oncotarget.28331
Abstract: Antibody drug conjugates (ADC) are one of the attractive modalities for the treatment of acute myeloid leukemia (AML). Previously, we have developed ASP1235, a novel ADC targeting Fms-like tyrosine kinase 3 (FLT3) which is widely… read more here.
Keywords: effect; combination; plus azacitidine; model ... See more keywords